UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

The lancet respiratory medicine, 2023-04, Vol.11 (4), p.354-366

2023

Volltextzugriff (PDF)

Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

Cancer science, 2011-02, Vol.102 (2), p.478-483

2011

Volltextzugriff (PDF)

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer

International journal of cancer, 2021-07, Vol.149 (1), p.169-176

2021

Volltextzugriff (PDF)

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1733-1744

2021

Volltextzugriff (PDF)

Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?

Journal of thoracic oncology, 2023-12, Vol.18 (12), p.1621-1624

2023

Volltextzugriff (PDF)

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis

Oncotarget, 2018-05, Vol.9 (37), p.24801-24820

2018

Volltextzugriff (PDF)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

Journal of clinical oncology, 2023-09, Vol.41 (26), p.JCO2300515-4217

2023

Volltextzugriff (PDF)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2019-08, Vol.11, p.1758835919870360-1758835919870360

2019

Volltextzugriff (PDF)

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

Journal of thoracic oncology, 2020-09, Vol.15 (9), p.1434-1448

2020

Volltextzugriff (PDF)

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation

Molecular cancer therapeutics, 2012-10, Vol.11 (10), p.2254-2264

2012

Volltextzugriff (PDF)

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

Future oncology (London, England), 2020-12, Vol.16 (34), p.2799-2808

2020

Volltextzugriff (PDF)

HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples

Future oncology (London, England), 2024-09, p.1-10

2024

Volltextzugriff (PDF)

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

Cancer cell, 2020-06, Vol.37 (6), p.742-745

2020

Volltextzugriff (PDF)

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

BMC cancer, 2011-10, Vol.11 (1), p.430-430, Article 430

2011

Volltextzugriff (PDF)

A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-04, Vol.166, p.17-26

2022

Volltextzugriff (PDF)

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lung cancer (Amsterdam, Netherlands), 2021-02, Vol.152, p.7-14

2021

Volltextzugriff (PDF)

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Journal of clinical oncology, 2024-10, Vol.42 (29), p.3400-3409

2024

Volltextzugriff (PDF)

A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

Nature communications, 2020-03, Vol.11 (1), p.1556-1556, Article 1556

2020

Volltextzugriff (PDF)

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Journal of clinical oncology, 2023-09, Vol.41 (26), p.4218-4225

2023

Volltextzugriff (PDF)

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer

Expert review of anticancer therapy, 2020-04, Vol.20 (4), p.233-240

2020

Volltextzugriff (PDF)

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-11, Vol.7 (11), p.1625-1630

2012

Volltextzugriff (PDF)

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Lung cancer (Amsterdam, Netherlands), 2019-01, Vol.127, p.103-111

2019

Volltextzugriff (PDF)

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.324-343

2020

Volltextzugriff (PDF)

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer

EMBO molecular medicine, 2018-06, Vol.10 (6), p.1-n/a

2018

Volltextzugriff (PDF)

26 – 50 von 469

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(426)
Mit Volltextzugriff
(417)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(305)
Life Sciences & Biomedicine
(275)
Humans
(212)
Oncology
(166)
Female
(103)
Male
(88)
Middle Aged
(75)
Lung Neoplasms - Drug Therapy
(71)
Mutation
(70)
Lung Cancer
(68)
Aged
(66)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(63)
Lung Neoplasms - Genetics
(63)
Adult
(62)
Respiratory System
(62)
Carcinoma, Non-Small-Cell Lung - Genetics
(53)
Tumors
(52)
Lung Neoplasms - Pathology
(51)
Patients
(50)
Non-Small Cell Lung Cancer
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(54)
Journal Of Thoracic Oncology
(35)
Lung Cancer
(22)
Cancer Research
(17)
Future Oncology
(10)
Oncotarget
(9)
Blood
(8)
Therapeutic Advances In Medical Oncology
(8)
Translational Lung Cancer Research
(8)
Clinical Cancer Research
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study

Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer

Suchergebnisse filtern